Next, we interrogated how potently EVT801 interfered with VEGFR-3 signaling in NCI-H1703 cells, and how it compared with the multi-RTK inhibitor pazopanib, which targets mainly VEGFR-1, VEGFR-2, VEGFR-3, FGFR-1, FGFR-3, B-raf, C-kit, and PDGFR, and was approved for the treatment of soft-tissue sarcoma, including Kaposi sarcoma and kidney cancer. Here, FGFR3 is linked to kidney cancer.